一个由MYC驱动的恶性循环是淋巴瘤中可准的阿基里斯脚跟
1Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
Blood cancer discovery
|June 14, 2023
概括
由MYC驱动的淋巴瘤生长依赖于转化因子eIF5A. 通过聚胺-氨酸通路的修改为治疗血液癌症的潜在治疗标.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 血液学 血液学 血液学
背景情况:
- MYC瘤蛋白驱动淋巴瘤的发展.
- 翻译启动因子eIF5A在细胞增殖中起作用.
研究的目的:
- 调查eIF5A活性在MYC驱动淋巴瘤的病变发生中的作用.
- 为了探索eIF5A的hypusination路径作为在淋巴瘤中潜在的治疗点.
主要方法:
- 在MYC驱动的淋巴瘤模型中分析eIF5A活性.
- 研究聚胺-氨酸电路及其由MYC的调节.
- 对抑制低化酶对淋巴瘤发展的影响的评估.
主要成果:
- 确定eIF5A的高活性对MYC驱动淋巴瘤的恶性生长至关重要.
- MYC 蛋白过激活了聚胺-氨酸电路,导致eIF5A 氨酸过激.
- 一种对eIF5A低化至关重要的酶被发现是淋巴瘤进展不可或缺的.
结论:
- eIF5A的低化是促进MYC驱动淋巴瘤的一个关键机制.
- 向低化通路,特别是负责eIF5A修饰的酶,为淋巴瘤提供了一个有前途的治疗途径.
- 这项研究强调eIF5A是血液癌症中潜在的药物标.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Induced Pluripotent Stem Cells
4.2K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.2K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


